Drug Profile
Research programme: MNK1/MNK2 inhibitors - Ryvu Therapeutics
Alternative Names: MKNK1/MKNK2 protein inhibitors; MNK1/2 kinase inhibitors - Ryvu Therapeutics; SEL201Latest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Selvita
- Developer Ryvu Therapeutics
- Class Small molecules
- Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Cancer in Poland
- 02 Oct 2019 Selvita is now called Ryvu Therapeutics
- 01 Nov 2015 Preclinical trials in Cancer in Poland (unspecified route)